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The aim of the study was to compare psychosocial outcomes for 50 new clinic attendees, referred for cancer genetic counselling to
five UK centres. The centres represented England, Scotland and Wales, and were randomly selected from groups ranked by different
levels of clinical activity in cancer genetics practice. Questionnaires assessed demographic data, risk perception, mental health and use
of health services pre-consultation and at 1 and 12 months follow-up. Satisfaction was measured for attendees and referring doctors
at follow-up. A total of 256 unaffected adults fulfilled the study criteria. The five centres varied widely with respect to service
organisation and activity, but all had a greater proportion of unaffected attendees with a breast cancer risk (61–91%) than either a
bowel cancer risk (0–33%) or ovarian cancer risk (3–25%). There were no significant differences in the psychosocial data between
centres pre-counselling. No significant change over time occurred for any of the centres for risk perception or general psychological
distress. There were significant differences between centres in reduction of cancer worry from baseline to 12 months and with the
number of women who were recommended to have mammographic surveillance who had not received this. Overall, one-third of
women for whom mammography had been recommended had not been screened within 1 year of follow-up. Subsequent
attendance at the GP, but not at a hospital, was associated with risk level, but differences between centres could not be analysed.
Satisfaction differed significantly between centres for 4 : 14 aspects of service provision and with 3 : 17 items concerning
communication; satisfaction was high overall. Over 90% of referring doctors were moderately/very satisfied with the service, but 23%
were dissatisfied with waiting times and 19% with access to preventive treatment. Results differed significantly between centres for
doctor’s satisfaction with the provision of referral criteria and prescribing information. In conclusion, there were relatively few
significant differences in psychosocial outcomes between centres, considering the wide variation in service organisation and activity.
These significant differences were not consistent across the centres, therefore, differences could not be linked to specific aspects of
service provision.
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Most NHS regionally based genetics centres now provide clinics
that deal specifically with risk assessment for familial cancers, such
as breast and colon cancers, in response to an increased demand
for information about cancer risks, for cancer screening and advice
on risk management. These cancer genetics services (CGSs)
have evolved in an ad hoc fashion according to local
expertise and resources. In phase one of this research (Wonderling
et al, 2001), the clinical activity of 22 of the 24 regional
CGSs was evaluated over the same 1-month period, in order to
describe the service provision nationally and make regional
comparisons. We found that all cancer genetics clinics were
dominated by referrals from families with a history of breast
cancer and there were significant variations between the
regions, for example in organisation of clinics, levels of staffing,
number of referrals per million population, waiting time for first
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appointment and risk level of families referred, and the results
implied that there were substantial variations in access to
molecular genetic testing and to cancer screening. The propor-
tion of referrals from primary care ranged from 29 to 70%, with
similar wide variations reported recently for South East Scotland
(Campbell et al, 2003).
It is important to know whether these service variations resulted
in different psychosocial outcomes for service users with respect to
their risk knowledge, mental health or health care behaviour.
Phase two of our study, presented here, was designed to address
this question. If there were significant differences, these could have
cost consequences and implications for the optimal use of available
NHS resources, as well as for the further development of regional
services. Prior to this study, psychosocial research had focused on
individual centres, evaluating the impact of risk counselling on
psychological status and risk perception in women at increased
risk of breast cancer. A meta-analysis of 12 of these studies (Meiser
and Halliday, 2002) has now confirmed a reduction in psycholo-
gical distress after genetic risk counselling, although the combined
results did not quite reach statistical significance. There was a
significant decrease in short-term anxiety and a significant
improvement in the accuracy of women’s perception of their
personal risk. While the benefit of anxiety reduction was short
lived, there was no evidence of an increase in general psychological
distress in studies with a longer follow-up, irrespective of whether
counsellees initially underestimated or overestimated their risk.
Therefore, there appears to be a beneficial effect of risk counselling
on the perceived risk accuracy without psychological detriment.
Meiser et al commented that it was not possible to include other
outcomes of risk counselling, such as mammographic screening
uptake, because of an insufficiency of studies; findings to date have
been inconsistent (Kash et al, 1995; Audrain et al, 1999; Schwartz
et al, 1999).
The benefit from risk counselling was further confirmed in a
recent systematic review of the psychosocial literature (Butow et al,
2003), based on two randomised controlled trials and seven
longitudinal studies. However, the strength of the conclusions was
considered to be limited by the lack of randomised study designs, a
problem addressed by the current research.
In the first study to compare the psychosocial outcomes of
different forms of service provision, Brain et al (2000) evaluated
the referred women who were randomly allocated to one of two
different service models for familial breast cancer within Wales.
Women who received risk counselling from a multidisciplinary
genetics team had a significantly greater improvement in risk
knowledge than those allocated to the surgical service, but this was
achieved with an increased service cost. No differences in mental
health or women’s satisfaction with the respective CGSs were
found; women’s anxiety and cancer worry decreased over 9
months following risk counselling in both arms of the trial. In the
most recent evaluation in South East Scotland, Fry et al (2003)
found no significant differences in psychosocial outcomes for
women referred to existing regional genetics services or a novel
community-based service, within a randomised trial. It is
important to know if these findings hold true for other UK
centres that differ from each other in size, organisation and
demands on service delivery.
In general, a deficiency in many psychosocial studies to
date has been the lack of systematic reporting of details of the
specific CGS and of the clinic population. This issue is addressed in
this study.
The aims of this phase 2 study were three-fold. First, in each
of five centres, to record the changes in risk perception,
psychological distress, health care behaviour and use of health
care resources in the year following cancer genetic counselling for
families with a history of cancer. Second, to ascertain satisfaction
with the service of both service users and their referring doctors
(GPs and hospital clinicians), and third, to describe regional
variations in outcomes that could be attributable to service
organisation or activity.
METHODS
Selection of centres
During phase 1 of the study, 22 of a possible 24 regional CGSs
were recruited to record all of their genetic counselling activity
over a pre-specified 4-week period. For the phase 2 studies, 20
centres (with full data available at the time of randomisation) were
ranked according to the rate of referrals received per million
population, as an indicator of service activity, and formed into five
sequential groups. One centre was then randomly selected from
each of these groups, and that centre asked to participate. By
chance, the five CGSs were located in regions in England, Scotland
and Wales.
Sample
Each CGS was required to recruit 50 individuals newly attending
for cancer genetic risk counselling. Individuals were excluded from
participation in the study if they had already been diagnosed with
cancer at any time or if they were under the age of 18. A nominated
member of the CGS staff recruited participants prior to their first
genetic counselling consultation. After reading an information
sheet and having an opportunity to ask questions about the study,
participants gave their written consent. They completed a
questionnaire booklet immediately prior to their first consultation
and the CGS clinician completed a study report form following the
consultation. Participants were sent follow-up questionnaires by
post 1 and 12 months after the initial consultation. At
approximately 6 months after recruitment, the doctor (GP or
clinician) who had referred the individual to the CGS was sent a
questionnaire to ascertain satisfaction with the service provided.
Response from participating service users and from their referring
doctors was encouraged by telephone reminders after 2 weeks and
written reminders 2 weeks later. Ethical approval for all aspects of
the study was obtained through the Multicentre Research Ethics
Committee.
Psychosocial measures
Psychosocial outcomes were assessed using patient self-report
questionnaires; where available, standardised measures were used.
Protocol-specific scales were derived from measures used in other
cancer genetics studies (Hopwood et al, 1998; Watson et al, 1998).
The data collected included the following:
Demographic information Patients were asked to indicate their
age, gender, ethnic background, level of education and occupation.
Genetic risk evaluation Perceived cancer risk was assessed using
a protocol-specific scale by asking subjects to rate their chances of
developing cancer compared to the general population, using five
response categories (very much lower–very much higher).
Psychological distress General mental health was assessed using
the 28-item General Health Questionnaire (GHQ) (Goldberg and
Williams, 1988), a self-report measure for detecting psychiatric
disorder in nonpsychiatry settings.
Cancer-specific distress Cancer worry, an indicator of cancer-
specific distress, was assessed using the modified Cancer Worry
Scale (CWS) (Watson et al, 1998; Hopwood et al, 2001), originally
developed by Lerman et al (1994). The six-item scale has been
shown to have good reliability (Brain et al, 2000; Hopwood et al,
2001), but no clinical case cutoff score is derived.
Genetic risk counselling services in UK
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Health care behaviour and use of health care resources
Health care behaviour was measured using protocol-specific
questions to ascertain the following: use of cancer screening tests
(e.g. mammography, colonoscopy, ovarian screening), breast self-
examination, clinical breast examination, attendance at the GP
surgery, well-woman check-ups, private health check-ups and
other hospital visits. Subjects were asked to indicate their
attendances for health care in the 6 months prior to the genetics
consultation (assessed at baseline), in the month following the visit
and in the 12 months following the visit.
Satisfaction with the CGS
Satisfaction with the service provided was assessed by counsellees
using a protocol-specific 14-item scale. Subjects were asked to
indicate their satisfaction on a four-point scale (not at all– very
satisfied).
Satisfaction with communication (Fallowfield, 1998)
Satisfaction with patient– clinician communication and key
aspects of the consultation was measured using a previously
tested 17-item scale (Fallowfield, 1998). Respondents were asked to
indicate their level of agreement (or disagreement) with positive
and negative statements about the consultation on a five-point
item response scale.
Satisfaction of referring doctors
Referring GPs and hospital clinicians were asked to indicate their
satisfaction with nine aspects of service provision, both in terms of
their overall impression of the local service and in respect of the
individual study participant they had referred.
Scoring and statistical analysis
The GHQ-28 was scored using the preferred binary (0–0, 1–1)
system giving an overall score on a scale from zero to 28, with higher
scores representing higher distress. A cutoff score of X10 was used
to indicate those individuals who were psychologically distressed
(after Hopwood et al, 1998). Item responses on the CWS were scored
1–4 for each question, giving a summary score of 6–24; higher
scores represented higher levels of worry. Satisfaction with patient–
doctor communication was evaluated using five-point responses,
scored 0–4, giving an overall score between zero and 68, with higher
scores representing higher satisfaction. Risk accuracy was assessed
by comparing perceived risks with clinician assessments within three
broad categories: population risk or marginally increased, sufficient
for screening (moderate risk) or family history indicative of possible
autosomal dominant mutation (high risk). Data were used to create
the following subgroups: accurate, overestimates or underestimates.
The study was designed with the intention of being descriptive
and hypothesis generating, and hence it was not powered to detect
differences between regions. However, statistical analyses were
conducted to see if the variability observed between regions could
have occurred by chance. The Kruskal–Wallis test was used for
waiting time and other quantitative variables. The Wilcoxon test
and McNemar’s test were used to analyse change over time in
quantitative and categorical data, respectively. The results
presented in this paper relate to the sample of patients who
responded to the pre-counsel and both follow-up questionnaires.
RESULTS
Participating centres
The characteristics of the five participating centres with respect to
service activity are shown in Table 1. Together, they served a
Table 1 Characteristics of participating cancer genetics services (CGSs)
Centre A Centre B Centre C Centre D Centre E
All five
CGSs
Regional data
Population (m) 2.9 5.2 3.1 2.2 0.5 13.9
Referral rate (per million
pop. p.a.)
130 208 268 298 353 225
No. of designated clinics
for cancer risk referrals
(and location)
0 2 (central hospitals) 6 (breast and cancer
clinics, local hospitals
and breast screening
unit)
10 (general hospitals) 1 (breast screening
unit)
19
No. of nondesignated clinics for
cancer risk referrals (and location)
7 (medical genetics
clinics)
422 across different
clinic sites
0 0 2 (medical genetics
clinics)
431
Service provision
Extent of genetic testing (% of
elevated risk)
25 31 26 32 18 26
Referral criteria (% sent
questionnaire)
6 89 39 88 70 59
Mammography provided
directly by CGS
No No Yes (some clinics) No Yes (some clinics) —
Median waiting time 19 23 29 26 31 24
% subjects seen in designated
CGS clinic
94 42 75 100 100 82
Staffing
Consultant (WTE) 1.0 1.0 0.7 1.0 0.4 4.1
Other medic. (WTE) 0.2 0.2 1.1 0.2 0.2 1.9
Genetic counsellor (WTE) 2.3 1.5 2.3 1.0 0.1 7.2
Dedicated cancer genetics
consultant
Yes No No Yes No —
% Subjects seen by CGS
consultant
53 58 56 76 100 70
% Subjects seen by CGS clinician 100 75 100 93 100 94
Genetic risk counselling services in UK
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population of 13.9 million (range 0.5–5.2 m) with a variation in
referral rate from 130 to 353 per million population per annum,
although these rates were not consequent on catchment size. The
mean number of sites for cancer genetics clinics per service was 10,
with a range from three to over 25 clinics in a range of locations.
Centre A had no designated cancer genetics clinics, while centres C
and D provided designated clinics at a total of 16 different
hospitals. The other two centres (B and E) provided both
designated CGSs and cancer genetics consultations within general
medical genetics clinics. Clinics were held in a variety of hospital
departments or screening units, and breast clinics. Across the
regions, clinic frequency ranged between two per week and one per
2–3 months, according to local demand and service organisation.
While other risk assessment services were thought to exist in each
region, three of the five centres had no precise knowledge of these
and two reported some awareness; centre A specified the Breast
Screening Unit and centre D specified the Breast Screening Unit,
Neurogenetics clinics and Dermatogenetics clinics. Staffing level/
type/grade, clinic type, waiting time and screening provision also
varied, consistent with findings for UK services as a whole
(Wonderling et al, 2001). The proportion of counsellees seen in
different locations (central clinic vs outreach) also varied widely.
Overall, general practitioners made 67% of referrals and specialists
(predominantly breast surgeons and gynaecologists) accounted for
34%. GP referrals varied significantly from between 52% (Centre
A) to 95% (Centre E), but there was little difference in the reported
reason for referral, with 89% or more of doctors specifying risk
assessment as the main reason. Both referral routes resulted in a
waiting time for appointment of up to 6 months for the majority of
referrals.
Sample characteristics
A total of 271 individuals consented to participate, of whom 256
fulfilled protocol criteria pre-counsel (range 49–52 by centre).
Reasons for exclusion after consent included cancer diagnosis (11)
and missing baseline questionnaire (4). Concurrent research
studies in two centres interfered with the plan to recruit
consecutive attendees and additional time was needed to accrue
the study sample in three centres. Thus, the sample can best be
described as a sample of convenience. Socio-demographic data
(shown in Table 2) revealed the same preponderance of women
from breast cancer families and lack of ethnic mix as described in
the national study (Wonderling et al, 2001). Differences in
proportions of subgroups partly reflected variations in recruitment
patterns. There were no differences in marital status and the
subgroups were generally representative of the cohort described
for the National study.
Compliance with self-assessments
Of the eligible sample, 91% provided questionnaire data at 1
month and 79% at 12 months: 75% provided data on all three
occasions. Participants who failed to provide follow-up data were
significantly younger in age (mean age 32.3 vs 41.3 years; Po0.001)
and comprised more individuals who perceived themselves to be at
population risk level (43 vs 37%; Po0.411).
Risk perception and change in relative risk accuracy
Using broad criteria for risk accuracy (population risk/elevated
risk), 63% of attendees perceived their relative risk of cancer in the
appropriate category as judged by the geneticist. There were three
times as many subjects underestimating (27%) as overestimating
(9%). These proportions were nonsignificantly reduced at 1 month
(21 and 8%, Po0.06; McNemar’s test) and at 12 months follow-up
(20 and 7%, Po0.581; McNemar’s test). There were no significant
variations between centres, as shown in Table 3.
Psychological distress (GHQ)
There was no difference between the centres in GHQ mean scores
at baseline or at either of the follow-up assessments (see Table 3)
and no significant change over time for any of the centres. The
prevalence of GHQ ‘probable cases’ for the full sample pre-
counselling was 13%. By centre, this rate ranged from 6 to 23%
pre-counselling, from 7 to 13% at 1-month follow-up and from 7 to
18% at 12-month follow-up, with no significant difference between
the centres. There was no significant change in the prevalence rate
over time (results for 162 subjects with full data).
Table 2 Sample characteristics
Centre A Centre B Centre C Centre D Centre E All five CGSs
Sample response
Pre-counsel 52 (100%) 52 (100%) 49 (100%) 52 (100%) 51 (100%) 256 (100%)
1 month 45 (86%) 45 (86%) 48 (98%) 48 (92%) 48 (94%) 234 (91%)
12 months 40 (77%) 37 (71%) 39 (80%) 43 (83%) 43 (84%) 202 (79%)
All three 36 (69%) 36 (69%) 39 (80%) 41 (79%) 40 (78%) 192 (75%)
Sociodemographics
Gender (% male) 6% 17% 0% 7% 0% 6%
Mean age (years), range 40 (24, 63) 41 (24, 72) 42 (23, 68) 43 (22, 67) 40 (23, 61) 41 (22, 72)
Ethnic minority 0 1 (3%) 3 (8%) 0 0 4 (2%)
University educated 61% 42% 62% 34% 35% 46%
Professional or managerial 50% 26% 53% 48% 31% 42%
Site of familial cancer
Breast 69% 61% 74% 71% 98% 75%
Bowel 6% 33% 23% 24% 0 17%
Ovary 25% 6% 8% 7% 3% 9%
Other 0 3% 3% 5% 0 2%
Risk level (clinician estimate)
Population-level risk 17% 14% 18% 20% 26% 19%
Moderate risk 35% 56% 50% 63% 69% 56%
High risk 48% 31% 32% 26% 5% 25%
Genetic risk counselling services in UK
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Cancer-specific distress (CWS)
At baseline, the mean cancer worry score for the overall sample
was 11.6 (s.d. 3.0) and the median score was 11.0 (range 6, 22).
Scores for the five centres are presented in Table 3, showing no
significant differences between centres at any time point. A small
but statistically significant reduction in cancer worry from baseline
to the 12-month follow-up was observed only for centres D and E.
However, combining the results for all the five centres, the mean/
median change in cancer worry scores between baseline and 12
months was statistically significant (Po0.001). Across centres,
reductions in the mean cancer worry scores from baseline to 1
month and from baseline to 12 months were similar for individuals
who initially underestimated their risk (0.3, 0.9) and for those
who initially overestimated (0.4, 1).
Health care behaviour
Results are considered for women with a breast cancer risk, who
formed the majority of attendees. Of 174 women with a breast
cancer family history, 148 (85%) had ever had a breast
examination, 40% in the 6 months before attendance at the
CGS and 51% at the clinic. In all, 104 (60%) of these women
had ever had a mammogram, 20% in the 6 months prior and
24% at the clinic visit. Results for 103 women deemed at
increased risk of breast cancer, as judged by the clinicians, were
comparable (see Table 4). There were no differences observed
between centres.
The proportion of women at elevated risk who were screened or
examined within a year of the cancer genetics consultation varied
significantly between centres, with between 54 and 100% receiving
mammography (Po0.001) and the same range having a clinical
breast examination (P¼ 0.003) (data not shown). Two centres with
low rates of reported access to mammography provided breast
examination for only half of the women at risk, but it is not known
whether this was routinely offered. Of note is the finding that 24%
women at increased risk, and aged 35– 49 years (the commonly
recommended age cutoff for starting mammography), did not have
a mammogram in the 6 months prior to or 12 months following
the genetics consultation (see Table 5); one in six of these women
did not have a breast examination. Overall, 87% women at any age
had one or other form of surveillance over this time period.
Table 3 Psychological distress (GHQ and CWS): mean and median scores and changes over time
Centre A Centre B Centre C Centre D Centre E All centers
Assessment point (n¼ 31) (n¼ 29) (n¼ 33) (n¼ 34) (n¼35) (n¼ 162)
Perceived personal riska Risk perception: Underestimators/all at elevated risk: n (%)
Pre-counsel 4/23 (17) 13/31 (42) 11/31 (35) 9/31 (29) 12/28 (43) 49/144 (34)
1 month 4/23 (17) 9/31 (29) 9/31 (29) 10/31 (32) 5/28 (18) 37/113 (33)
12 months 5/23 (22) 7/31 (23) 9/31 (29) 9/31 (29) 6/22 (27) 36/109 (33)
GHQ Mean, Median Mean, Median Mean, Median Mean, Median Mean, Median Mean, Median
Pre-counsel 4.8, 3.0 3.0, 0 3.5, 2.0 2.8, 1.0 3.3,1.0 3.4, 1.5
1 month 3.4, 0 2.3, 0 3.5, 1.0 2.6, 0 3.0, 0 3.0, 0
12 months 3.5, 1.0 2.9, 3.0 4.8, 4.0 3.3, 1.0 2.6, 2.0 3.4, 1.0
12-month pre-counselb (P value)c 1.29, 0 (P¼ 0.203) 0.3, 0 (P¼ 0.983) 1.3, 0 (P¼ 0.200) 0.5, 0 (P¼ 0.492) 0.7, 0 (P¼ 0.639) 0.2, 0 (P¼ 0.995)
CWS (n¼ 35) (n¼ 32) (n¼ 39) (n¼ 38) (n¼38) (n¼ 182)
Pre-counsel 11.1, 10 12.0, 12 11.0, 10 12.6, 11 11.2,11 11.6, 11
1 month 11.2, 10 11.1, 11 10.6, 10 11.1, 10 10.6, 10 10.9, 10
12 month 10.8, 10 11.0, 10 10.5, 10 11.4, 11 10.2, 10 10.8, 10
12-month pre-counselb (P-value) 0.3, 0 (P¼ 0.375) 1.0, 1 (P¼ 0.191) 0.5, 0 (P¼ 0.107) 1.3, 1.5 (P¼ 0.005) 1.0, 1 (P¼ 0.012) 0.8, 1 (Po0.001)
aThe ‘mean change’ and ‘median change’ for GHQ summary scores and ‘mean change’ and ‘median change’ for CWS summary scores are shown. bSample excludes subjects
deemed by the genetics clinician to be at population risk. cWilcoxon signed rank test: Shown are ‘mean change’ and ‘median change’ for GHQ summary scores and ‘mean change’
and ‘median change’ for CWS summary scores.
Table 4 Health care behaviour: reported use of cancer screening tests
Tests carried out on subjects with an increased risk (n (%))
Ever In 6 months prior At clinic In 1 month since In 12 months since
Increased breast cancer risk (n¼ 103)
Breast exam 90 (87%) 47 (46%) 53 (51%) 4 (4%) 25 (24%)
Mammogram 61 (59%) 20 (19%) 22 (21%) 5 (5%) 27 (26%)
Breast U/S 32 (31%) 11 (11%) N/K 0 (0% ) 6 (6%)
CA125 27 (26%) 10 (10%) N/K 5 (5%) 15 (15%)
Ovarian other 21 (20%) 2 (2%) N/K 1 (1%) 5 (5%)
Increased bowel cancer risk (n¼ 28)
CA125a 1 (5%) 0 (0%) N/K 0 (0%) 0 (0%)
Ovarian othera 4 (19%) 1 (4%) N/K 0 (0%) 1 (5%)
Colonoscopy 15 (54%) 10 (36%) N/K 1 (4%) 11 (39%)
aWomen only (n¼ 21).
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Numbers of individuals eligible for other cancer-screening tests
were too few in number for comparisons between the centres, but,
overall, only 54% individuals at risk for bowel cancer had ever had
a screening test, of whom 36% had already undergone screened in
the 6 months prior to attendance.
Breast self-examination habits were assessed at 1 and 12 months
follow-up. Results showed no significant variation between centres
(P¼ 0.6, data not shown). A modest rate (40%) of usage of the
frequently recommended monthly breast checking was reported
overall, which remained stable over time, irrespective of the type of
cancer risk. Women with a breast cancer family history were more
likely to be excessive checkers (4once a week) than those with
other cancer risks, both at 1-month follow-up (11 vs 0%) and at 12
months (9 vs 3%) (data not shown). Fewer women with a breast
cancer history reported never checking compared with those with
other cancer family histories (5 vs 21% at 1 month and 10 vs 18% at
12 months).
Use of clinical breast examination assessed at 12 months follow-
up varied between 67 and 100% overall, across centres. Rates for
women deemed at increased risk are shown in Table 5 and were
uniformly high.
Use of health care resources
Female participants were also asked about the use of specific
health care resources, both before and following the genetic
consultation. Numbers using such resources were too small to
analyse by centre; therefore data are combined. Most counsellees
did not have any contacts with the health service in the month
following their consultation. Those returning to the CGS did so for
a variety of appropriate reasons (data not shown). The likelihood
of having a primary care appointment during the month varied by
risk level (population risk 11%, moderate risk 19%, high risk 34%),
but the likelihood of a hospital appointment did not. Table 6 shows
that, for women with a breast or bowel cancer risk, 53 and 59%,
respectively, made hospital visits and 71 and 65% had GP
consultations in the year following the genetics consultation.
A minority of subjects (30.13%) changed their lifestyles since the
consultation. In all, 12 (10 women and two men) adopted a
healthier diet (more fruit and vegetables and less fat) and seven
reduced weight. One stopped smoking and three reduced their
alcohol intake. Numbers were too small for comparison by centre.
Attendees’ satisfaction with the CGS
Across all centres, satisfaction was reported as high at 1 and 12
months follow-up for all 14 aspects of service activity. The areas
associated with greatest dissatisfaction are shown in Table 7,
showing that 30% were dissatisfied with the availability of genetic
testing and with information about cancer prevention strategies.
Comparison of centres showed significant differences in dissatis-
faction for risk management advice, having a cancer test/screening
X-ray, information on genetic testing and lifestyle advice. The
Table 5 Reported use of mammography and clinical breast examination
for female study participants, by age
Examinations for women at elevated risk of breast cancer, by agea
(all time points included)
Mammography
Clinical breast
exam
Clinical breast
exam or
mammography
Ageo35 5/37 (14%) 31/37 (84%) 32/37 (86%)
Age 35–49 38/50 (76%) 42/50 (84%) 45/50 (90%)
Age 50–65 10/15 (67%) 12/15 (80%) 12/15 (80%)
All 54/103 (52%) 86/103 (83%) 90 /103 (87%)
aOnly one woman aged over 65 years.
Table 6 Health care visits since first cancer genetics consultation
Health care resource In following 1 month
In following 12
months
Women with increased breast
cancer risk (n¼ 105)
Revisit CGS 10 10% 20 19%
Other hospital visit 20 19% 56 53%
GP surgery 36 34% 75 71%
Well-woman clinic 4 4% 8 8%
Family-planning clinic 2 2% 4 4%
Private health check 0 0% 4 4%
Women with increased bowel cancer risk (n¼ 22)
Revisit CGS 1 6% 4 24%
Other hospital visit 3 18% 10 59%
GP surgery 8 47% 11 65%
Well-woman clinic 0 0% 1 6%
Family-planning clinic 1 6% 2 12%
Private health check 0 0% 0 0%
Table 7 Attendees reported satisfaction with overall service and with communication: comparison by centre
CentreA Centre B Centre C Centre D Centre E All centres
Satisfaction item % less than moderately satisfied
Plans for future screening 16 13 17 13 15 15
Risk management advice 17 3 26 7 30 17a
Wait for first appointment 11 6 22 22 29 18
Having cancer test/X-ray 12 25 41 13 3 16a
Info. on genetic test 13 13 41 15 23 20a
Lifestyle advice 23 14 39 9 41 27a
Availability of genetic test 22 30 39 18 42 30
Information re. prevention 20 22 40 17 45 30
Fallowfield Satisfaction Scale – Mean (SD) summary score
1 month 62.1 (8.6) 64.2 (4.7) 57.8 (8.3) 63.4 (5.5) 59.5 (8.9) 61.3 (7.7)b
12 months 62.2 (7.3) 63.1 (5.6) 58.7 (8.6) 59.2 (10.1) 59.9 (8.0) 62.1 (8.3)c
aSignificant at 5%. None were significant at 1%. bSatisfaction with initial CGS consultation (N¼ 176): P¼ 0.02; Kruskal –Wallis test. cSatisfaction with initial/most recent CGS
consultation (N¼ 171; 138 had not returned to the CGS): P¼ 0.08; Kruskal –Wallis test.
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median waiting time for the first appointment varied significantly
between centres from 19 to 31 weeks (Po0.001), but was
associated with dissatisfaction for only 18% respondents overall,
and this did not vary significantly between the centres. There was
very little difference in satisfaction ratings at the two follow-up
points, except for satisfaction with information given about the
centre, which changed from 79 to 91% (data not shown).
Satisfaction with communication
Satisfaction with the genetic consultation focused more specifically
on communication and clinician style. Summary scores ranged
between 57.0 and 64.2, with little change over the length of follow-
up. There were significant differences between centres (see
Table 7), with three items contributing to this variance: waiting
too long to be seen at the clinic, not being told what the counsellee
wanted to know and the doctor not seeming sympathetic (data not
shown). No one centre was linked to dissatisfaction on all three
items.
Referring doctors’ satisfaction
Questionnaires were sent to 198 doctors who had referred 238
participating subjects (range 1– 10). Forms were returned by 116
(58.5%) doctors (67 GPs, 34 clinicians): three doctors were
excluded as their role was integral to the genetics service and 79
(40%) doctors failed to reply. Reasons for noncompliance, where
known, were: doctor or patient had left the practice (n¼ 10);
doctor had not made the referral himself (n¼ 4); doctor too busy
(n¼ 2).
As shown in Table 8, over 90% of doctors responding were
moderately or very satisfied with information about the patients’
cancer risk, about cancer screening recommendations and with
feedback in general from the genetics centre. However, 23%
doctors (31% of GPs and 11% of specialists) were dissatisfied with
the waiting time for an appointment, 18% (21% of GPs and 13%
of specialists) were dissatisfied with referral criteria and 19%
(20% GPs and 18% specialists) were dissatisfied with
access to preventive treatment. There were significant differences
in satisfaction between the centres for referral criteria
and information about prescribing, such as use of hormone
replacement therapy or the contraceptive pill. Specialists
were more dissatisfied with information about prescribing than
GPs (23 vs 6% GPs).
Centres associated with significant differences in doctors’
dissatisfaction were different from those associated with signifi-
cant differences in attendees’ dissatisfaction, so that no particular
service model appeared to be disadvantaged.
DISCUSSION
This is the first direct comparison of psychosocial outcomes
following genetic risk counselling for individuals with a family
history of cancer in a UK-wide study of CGSs. In line with
randomised comparisons carried out in Wales and South East
Scotland, significant differences in psychosocial outcomes between
the centres were small in number, with no discernible pattern in
the centres concerned. Therefore, differences are unlikely to reflect
a specific type of service configuration. The positive implication
for the NHS is that service users will have similar psychosocial
benefits despite wide variation in current service provision.
At first sight, the lack of differences may seem surprising, given
evidence of wide variation in service structure, organisation and
clinical workload (Wonderling et al, 2001). At the time the study
was undertaken, CGSs were evolving to meet the model
recommended by the Harper report (Working Group for the Chief
Medical Officer, 1998), and other published information and
guidelines (Murday, 1994; Ponder, 1994; Priority Areas Cancer
Team, 1998; Eccles et al, 2000). It is possible that the information
transferred in genetic risk counselling was broadly similar between
centres, as a result of close collaboration within the genetics
community, at a clinical and research level. We cannot be sure that
differences in psychosocial outcomes do not exist for other CGSs
throughout the UK, but the random selection of centres based on
clinical activity levels in this study provides some basis for
confidence in the findings, as extremes of variation were covered,
and a consistent methodology applied. It is difficult to estimate the
extent or impact of other risk counselling activity provided
separately through breast clinics and community health settings, as
no data are available.
This multicentre study confirms earlier published findings
(Meiser and Halliday, 2002) that risk counselling is not harmful to
general mental health, and achieves a modest effect on reducing
cancer worry following a single consultation. Whether this benefit
has an impact on risk management and health care behaviour
cannot be shown by our findings, and warrants investigation. We
were unable to show marked changes in risk perception, in
contrast to published literature (Meiser and Halliday, 2002), but
this is likely to reflect the variation in the type of cancer risks and
the risk level in the study sample, which limited examination in
detail. The impact of continued misperception of risk on health
care behaviour and use of health resources remains to be
determined.
The study also identified variations between centres that warrant
attention. First, there were significant differences in the use of
mammographic surveillance, which may partly reflect the lack of a
national screening policy for high-risk women below the age of 50.
Other factors could be a lack of access to mammography
provision, poor communication at the interface between tertiary
Table 8 Referring doctors satisfaction with the cancer genetics service
Centre A Centre B Centre C Centre D Centre E All centres
Satisfaction item % Not at all satisfied/only a little satisfied
Referral criteria 5 16 28 8 20 18a
Waiting time for appointment 25 17 13 25 37 23
Feedback from CGC 0 0 0 4 6 2
Information about risk level 4 4 0 11 6 6
Information about screening 10 12 7 4 12 9
Prescribing information 22 0 11 9 15 11a
Information about risk management 13 5 8 4 24 11
Access to screening 5 13 14 15 12 12
Access to prevention 17 21 25 18 14 19
aCentres are significantly different at 5% (Kruskal –Wallis).
Genetic risk counselling services in UK
P Hopwood et al
890
British Journal of Cancer (2004) 91(5), 884 – 892 & 2004 Cancer Research UK
C
lin
ic
a
l
and primary care, or poor uptake/compliance with mammography,
which were beyond the scope of this study. However, two
initiatives should help to resolve this regional inequity and clarify
the role of breast surveillance in this setting: these are the National
Institute of Clinical Excellence (NICE) Clinical Guidelines for the
classification and care of women at risk of familial breast cancer
(NICE, May 2004; McIntosh et al, 2004), and the NHS Research and
Development Health Technology Assessment evaluation of mam-
mographic surveillance of women of age 40–49 with a family
history.
The NICE guidance will also address areas of dissatisfaction
raised by referring doctors, which warrant improvement. These
concerned referral criteria and prescribing advice, while, for both
doctors and attendees, there was perceived inadequacy of
information about preventive options and access to genetic testing.
Evidence is accumulating to support risk management interven-
tions, such as risk-reducing mastectomy (Hartmann et al, 1999;
Meijers-Heijboer et al, 2001), to help inform clinical decision-
making, so that differences between centres observed here should
gradually be eliminated. Clear criteria for referral to tertiary care
and access to genetic testing will be provided in the NICE
guidelines, reducing the potential for future dissatisfaction.
There were high levels of satisfaction across settings, in
contrast to findings by Brain et al (2000), but significant
differences in satisfaction between centres were observed for a
small number of aspects of the consultation itself. This reflects the
general need for identification of optimal risk communication
strategies (Julian-Reynier et al, 2003) and communication training
(Fallowfield et al, 2002). More obvious differences between centres,
such as waiting time for the first appointment, did not
discriminate levels of satisfaction between service users, but did
cause dissatisfaction among referring doctors, and should be
improved.
Differences between centres were not seen for primary care
consultations or use of other health care resources following risk
counselling, but the level of cancer risk did impact on resource use.
Research initiatives have been undertaken to assist primary care
teams in the identification of moderate and high-risk families who
warrant further advice (Emery et al, 1999, 2000), so that
individuals can be properly triaged for primary care support,
cancer screening or cancer genetic referral. Use of health services
in the year after the cancer risk consultation are difficult to
interpret in the absence of a control group which did not receive
genetic counselling, but hospital attendance rates did appear to
increase, probably reflecting the need for cancer screening; this
could be audited in light of the new service guidelines. Cancer
genetics services can be an important means of optimising
resource use through making appropriate recommendations to
individuals most likely to benefit.
In contrast to other published work, we planned to evaluate a
representative mix of individuals with different cancer risks, but all
the five centres were dominated by referrals of women with a
family history of breast cancer so that data are limited for smaller
risk subgroups. For subjects with a risk of bowel cancer, the next
largest subgroup, rates for colonoscopy usage were reported as
lower than for screening mammography, but it is not possible to
say whether this reflects lack of access or of uptake. Lower than
expected rates of recruitment for colonoscopy have been reported
elsewhere, and both discomfort and risks associated with the
procedure were thought to be contributory factors (Eisinger et al,
2001). Other subgroups were too small for analysis. Women with a
bowel cancer risk were less vigilant about breast self-examination
and it is important that clear health care messages, such as the
need to be ‘breast aware’, are provided for all women.
Strengths of the study design included the use of standardised
assessments and the participation of randomly selected centres
representing wide variation in service provision. Compliance with
mailed questionnaires was generally good, but responses from
referring doctors were lower. Some limitations are also acknowl-
edged. The case mix and small sample quota from each centre,
limited for logistical reasons, resulted in some lack of precision
with which some outcomes could be assessed. Therefore, the study
was designed to be descriptive rather than hypothesis testing.
Gender and ethnic differences could not be evaluated and effort
will be needed nationally to ensure appropriate representation of
men and ethnic minorities in these clinics.
In conclusion, in the absence of differences in psychosocial
outcomes, centres will need to think carefully about appropriate
end points to evaluate the development of their particular service.
There is now clear evidence of the information needs and
perceived inadequacies of care as well as the level of mental
health and satisfaction that can be achieved in this setting, that will
form standards for future studies.
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